Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) is a highly prevalent condition strongly associated with adverse outcomes; it significantly increases cardiovascular risk and mortality in this population. One of the most frequent echocardiographic findings is concentric left ventricular remodeling. Although this alteration results from abnormal cardio-renal interactions, it is important to identify predictors associated with this pathology.
This is a cross-sectional observational study of 195 patients with stage 5 CKD undergoing renal replacement therapy (95 on hemodialysis [HD], 100 on peritoneal dialysis [PD]) from a retrospective clinical database. Inclusion criteria: patients over 18 years old and at least 3 months since starting renal replacement therapy. Exclusion criteria: incomplete data for key variables of interest. Variable definitions: Left Ventricular Remodeling (LVR): Dichotomous variable based on standardized echocardiographic criteria; categorized as presence of concentric or eccentric remodeling or left ventricular hypertrophy. Myocardial Ischemia (MI): Dichotomous variable defined as the presence of any chronic coronary syndrome or acute myocardial infarction. Dialysis Modality: Dichotomous variable, categorized as HD and PD (PD as the reference group). Mineral Bone Disorder (MBD): Categorical (yes/no), defined by any of the following: PTH > 300 pg/mL, phosphorus > 5.5 mg/dL, or calcium < 8.5 mg/dL. Urine Output: Ordinal variable: 1 = <500 mL/day; 2 = 500–1000 mL/day; 3 = >1000 mL/day. CKD duration: Ordinal variable: 1 = <5 years; 2 = 5–10 years; 3 = >10 years. Other variables: Age (continuous), sex (male/female). Descriptive analysis: Frequencies and percentages were calculated for categorical variables; means and standard deviations for continuous variables. LVR and MI prevalence were estimated globally and by dialysis modality as well as MBD status. Statistical modeling: Multivariable logistic regression models were used to identify independent factors associated with LVR and MI. Predictors included: dialysis modality, MBD, age, sex, urine output, and CKD duration. An interaction term (HD×MBD) was added to assess effect modification. Model performance was evaluated using ROC curves and AUC. Statistical significance was set at p < 0.05. Analyses were performed using SPSS v26 (Windows). Tests used: Mann–Whitney (non-normal variables), Student’s t-test (normal), Chi-square or Fisher’s exact (categorical). Objectives: To determine the prevalence of left ventricular remodeling (LVR) and myocardial ischemia, as well as their predictive factors in patients with end-stage CKD on HD or PD.
his study included 195 patients, mean age 47.3 ± 12.4 years, 47.7% female. Overall MBD prevalence: 74.4%, with no significant PTH differences between HD (476.45 ± 489.17 pg/mL) and PD (488.91 ± 515.20 pg/mL; p = 0.871). Cardiovascular Phenotypes; Global LVR prevalence: 54.4% (106/195). Myocardial ischemia prevalence; 13.3% (26/195). Factors Associated with Left Ventricular Remodeling: The multivariable logistic regression model showed no statistically significant variables, though trends were seen for HD (OR 1.51; 95%CI 0.83–2.74; p = 0.174), MBD (OR 1.45; 95%CI 0.74–2.85; p = 0.279), and ischemia (OR 1.70; 95%CI 0.70–4.18; p = 0.244). Stratified analysis of MBD showed a strong trend with LVR (OR 2.45; 95%CI 0.89–6.74; p = 0.084), whereas in HD no effect was seen (OR 0.92; 95%CI 0.34–2.50; p = 0.866). A random-effects model with the HD×MBD interaction indicated HD was a significant predictor of LVR (OR 3.37; 95%CI 1.02–11.08; p = 0.046), with an attenuated MBD effect in HD. Factors associated with myocardial ischemia: trends suggested a protective effect of the HD therapy (OR 0.43; 95%CI 0.17–1.08; p = 0.072) and male sex association (OR 2.09; 95%CI 0.81–5.39; p = 0.127). LVR showed a nonsignificant positive association (OR 1.72; 95%CI 0.68–4.34; p = 0.250).
Variable
PD (n=100)
HD (n=95)
p
DEMOGRAPHICS
Age, years
49.0 [39.9–58.1]
50.0 [40.0–60.0]
0.548
Weight, kg
66.8 ± 12.6
66.6 ± 14.0
0.924
BMI, kg/m²
24.8 [22.7–27.0]
24.7 [21.6–27.7]
0.802
Male sex, n (%)
53 (53.0%)
40 (42.1%)
0.128
COMORBIDITIES
Diabetes mellitus, n (%)
40 (40.0%)
32 (33.7%)
0.361
Hypertension, n (%)
88 (88.0%)
85 (89.5%)
0.745
DIALYSIS PARAMETERS
Urine output, n (%)
69 (69.0%)
75 (78.9%)
0.192
• >1000 mL/day (category 3)
10 (10.0%)
9 (9.5%)
• 500–1000 mL/day (category 2)
21 (21.0%)
11 (11.6%)
Mineral Bone Disease (MBD), n (%)
37 (37.0%)
49 (51.6%)
0.062
LABORATORY
Hemoglobin, g/dL
11.0 ± 1.9
11.8 ± 2.1
0.006
Hematocrit, %
32.0 [28.3–35.7]
36.9 [32.9–40.9]
0.001
WBC, ×10³/µL
6.3 [4.7–7.9]
6.3 [5.1–7.4]
0.555
Platelets, ×10³/µL
268.0 [212.8–323.2]
206.0 [167.2–244.8]
<0.001
Glucose, mg/dL
92.0 [81.0–103.0]
86.0 [77.0–95.0]
Total cholesterol, mg/dL
165.0 [138.8–191.2]
152.0 [124.0–180.0]
0.075
Sodium, mEq/L
137.0 [135.0–139.0]
138.0 [136.0–140.0]
0.730
Calcium, mg/dL
8.9 [8.4–9.4]
9.1 [8.4–9.8]
0.498
Phosphorus, mg/dL
5.8 [4.4–7.2]
4.7 [3.5–5.9]
0.003
PTH, pg/mL
323.0 [63.8–582.2]
310.0 [18.5–601.5]
0.911
ECHOCARDIOGRAPHY
LVEF (echo), n (%) - Preserved
92 (92.0%)
90 (94.7%)
0.639
• Slightly reduced
6 (6.0%)
3 (3.2%)
• Reduced
2 (2.0%)
2 (2.1%)
Pulmonary hypertension, low probability (echo), n (%)
79 (83.2%)
0.308
• Intermediate probability (echo)
10 (10.5%)
• High probability (echo)
6 (6.3%)
Cardiac catheterization, n (%)
17 (17.0%)
12 (12.6%)
0.391
CV OUTCOMES
LV Remodeling (echo), n (%)
50 (50.0%)
56 (58.9%)
0.210
Ischemia, n (%)
18 (18.0%)
8 (8.4%)
0.049
Abbreviations: PD = peritoneal dialysis; HD = hemodialysis; BMI = body mass index; MBD = mineral bone disorder; LVEF = left ventricular ejection fraction; PTH = parathyroid hormone.
Continuous data are shown as mean ± SD (if normal) or median [IQR] (if non-normal); categorical as n (%). p calculated by Student’s t-test or Mann–Whitney; χ² or Fisher as appropriate. p < 0.001 shown as <0.001.
This study demonstrates considerable heterogeneity in the effect of MBD on LVR depending on dialysis modality. The MBD–LVR association was evident among PD patients but attenuated among HD patients. These findings suggest physiopathological differences between modalities may modulate the cardiovascular impact of mineral abnormalities. For myocardial ischemia, the protective trend seen with HD may relate to better cardiovascular risk factor control, though prospective studies are needed to confirm this. These findings support developing tailored management strategies by renal replacement therapy modality.
